Episode Details

What if your thyroid gland isn’t just a chemical factory—but a light-sensing organ with the hardware to “see”? In this Energy Code Deep Dive, we unpack a jaw-dropping paper: “Wearable Photobiomodulation Halts Thyroid Cancer Growth by Leveraging Thyroid Photosensitivity.” The study suggests papillary thyroid carcinoma cells express opsins(photoreceptor proteins like those in the retina)—specifically a short-wavelength opsin tuned for blue light. Researchers ran a “wavelength war” (red vs green vs blue) and found 465 nm blue light uniquely halted cancer growth, first by cell-cycle arrest and then—inside living animals—by triggering apoptosis (cell self-destruction). Even wilder: they engineered a battery-free, NFC-powered wearable that delivered a precise dose over weeks, suppressing tumors while leaving thyroid hormone function intact. This episode reframes light as an instruction set—and asks the bigger question: are we “light malnourished” in a world spent indoors?

(Educational content only, not medical advice.)

-

Article Discussed in Episode:

Wearable photobiomodulation halts thyroid cancer growth by leveraging thyroid photosensitivity

-

Key Quotes From Dr. Mike:

“They discovered the thyroid itself is a non-visual photoreceptive organ.”

“The thyroid has a built-in antenna for blue light.”

“We’ve been ignoring the optical anatomy of the human body.”

“Light is an instruction set for the world inside of us.”

“Maybe our internal organs are literally starving for the right kind of light.”

-

Key points

1. The thyroid may be photoreceptive: thyroid cancer cells were found to contain opsins, the same class of light-sensing proteins used for vision.

2. OPN1SW shows up in thyroid cancer: a short-wavelength opsin suggests the tissue is tuned to blue lightsignaling.

3. PBMT ≠ PDT: photodynamic therapy requires injected dyes; photobiomodulation uses intrinsic biology—no photosensitizer needed.

4. A “wavelength war” identified the winner: red (650 nm) and green (520 nm) did nothing; blue (465 nm) significantly inhibited proliferation.

5. Mechanism in vitro: cell-cycle arrest: blue light trapped cells in G0/G1, increasing P21 (brake) and decreasing CDK4 (gas pedal).

6. Dose matters: effects were dose-dependent, with an optimal 24-hour cycle delivering 172.8 J—“light is a drug.”

7. Blue light penetration challenge addressed: in 3D tumor spheroids, the blue light still reduced tumor volume over 7 days.

8. Real-world delivery required engineering: a thin wireless wearable patch powered by NFC (tap-to-pay tech) delivered therapy without a battery.

9. In vivo effect: apoptosis: in mice, tumors didn’t just pause—they underwent programmed cell death.

10. Why dish vs body differs: possible “endogenous photosensitizers” generated by metabolism and/or immune involvement in living systems.

11. Safety profile stood out: thyroid hormones (T3/T4) remained stable; no weight loss; no liver/kidney toxicity markers.

12. Paradigm shift: suggests a future of organ-preserving, non-invasive metabolic/energetic medicine—and expands the idea that organs may be energy “antennas.”

-

Episode timeline 

0:19–1:16 — Hook: organs that can “see”

The thyroid as a light-sensing organ; intro to the study and why